Close Menu


The test leverages ELISA technology and uses non-pathogenic viral proteins, enabling its use in common lab settings either manually or automatically.

Oncgnostics also expects the test to be approved by regulators in Canada and to be sold there by the end of the year.

While the human toll of the disease has been terrible, IVD makers also report there have been some positive developments, as demand has spiked and familiarity with testing has grown.

News items for the in vitro diagnostics industry for the week of March 8, 2021.

The firm plans to use $561 million of the net proceeds to fund the majority of its planned $591 million acquisition of Oxford Immunotec.

The firm said its T-cell test complements serology testing and provides a more comprehensive view of the adaptive immune response to SARS-CoV-2 infection.

The test qualitatively detects SARS-CoV-2 nucleocapsid protein antigen in nasal or nasopharyngeal swab specimens and provides results in as little as 15 minutes.

The firm's Discovery and Analytical Solutions business revenues grew 1 percent year over year, while its Diagnostics revenues more than doubled.

News items for the in vitro diagnostics industry for the week of Jan. 25, 2021.

The firm has collaborated with Novartis to help pilot the new sickle cell disease test and a treatment in Ghana.